For example, inclusion criteria are examined for the use of Herceptin, and approximately 120 to 140 patients with breast cancer are allowed to receive the treatment for free every year. The number of eligible women is expected to be raised to 200 in coming years. Ineligible patients, however, are required to pay the entire cost of Herceptin.